How can I model large molecules like macrocycles?
What comprises large molecules? When we talk about “large molecules,” we often think of biologics like monoclonal antibodies, proteins, and…
What comprises large molecules? When we talk about “large molecules,” we often think of biologics like monoclonal antibodies, proteins, and…
Benefits of continuous integration to use up-to-date data in model building Cerella has the ability to work with and learn…
Is AI-guided drug discovery faster and cheaper? The evidence for this is, by definition, anecdotal. No one runs the same…
The role of generative chemistry in drug discovery A key difficulty in finding new drugs is the sheer size of…
In this ebook, you’ll discover the key considerations which every leader needs to take in order to successfully implement AI in their drug discovery pipelines.
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
Generative molecular design provides new exciting avenues of chemical space exploration. But how can we use these methods effectively to assess many optimisation strategies and find the compounds destined for success in our projects?
Join Dr Matt Segall and Dr Michael Parker as they explore state-of-the-art generative chemistry, and discuss the importance of an augmented intelligence approach for successful discovery.
Join Daniel Barr to hear more about how deep learning imputation prioritises the most relevant data, accounts for uncertainty, and guides experiment selection to bring additional value to small molecule discovery.
Join Optibrium’s Chris Khoury at the 38th NMCS meeting in Seattle, 23-26 June
Join Optibrium at HubXchange in Boston to hear more about implementing AI in drug discovery.
Version This integration is available to use with the latest version of StarDrop (Windows and macOS). To find out which version…
Have advances in AI and deep learning reached a threshold whereby generative chemistry methods are redefining drug design? This webinar…
In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry. Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.
This article is a collaboration with Intellegens, the University of Cambridge and AstraZeneca. It provides a proof-of-concept study in which Cerella™ is used to predict rat in vivo pharmacokinetic (PK) parameters and concentration–time PK profiles.
In this study, we identified a new antimalarial with an unusual structure – the only compound in the competition to be proven active, opening up new chemistry for exploration.